Serum tumour markers in gynaecological cancers

被引：60

作者：

Aggarwal, Pakhee ^{[1
]}

Kehoe, Sean ^{[1
]}

机构：

[1] Churchill Hosp, Oxford Gynaecol Canc Ctr, Dept Gynaecol Oncol, Oxford OX3 7LJ, England

来源：

MATURITAS | 2010年 / 67卷 / 01期

关键词：

Serum tumour markers; Ovarian cancer; Endometrial cancer; CA125; Cervical cancer; GERM-CELL TUMORS; OVARIAN-CANCER; ENDOMETRIAL CANCER; CERVICAL-CANCER; ALPHA-FETOPROTEIN; CARCINOMA ANTIGEN; PROGNOSTIC FACTOR; CA125; EXPRESSION; FOLLOW-UP; INHIBIN-B;

D O I：

10.1016/j.maturitas.2010.04.017

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Serum tumour markers have had a role in screening, diagnosis and monitoring of some gynaecological cancers. Women with suspected ovarian malignancies have as routine a CA125 serum test, and in conjunction with scans, the risk of malignancy can be calculated. Equally, this CA125, if elevated pre-operatively can be used to predict chemotherapeutic responses, and even disease relapse prior to any symptoms or clinical findings. Other useful markers in ovarian cancer are beta HCG and AFP produced by germ cell tumours. beta HCG is also of extreme importance in both the diagnosis and management of choriocarcinomas. The level of beta HCG determines the need, and with other indicators, the type of chemotherapeutic intervention. Other serum markers are known in cervical cancer, and possibly endometrial and vulval cancer-but their clinical utility is very limited. Novel markers may help in managing patients, and in the future permit screening for certain diseases. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：46 / 53

页数：8

共 65 条

[11] Tissue and serum CA125 expression in endometrial cancer [J].

Ginath, S ;

Menczer, J ;

Fintsi, Y ;

Ben-Shem, E ;

Glezerman, M ;

Avinoach, I .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2002, 12 (04) :372-375

[12] Measurement of dimeric inhibin B throughout the human menstrual cycle [J].

Groome, NP ;

Illingworth, PJ ;

OBrien, M ;

Pai, R ;

Rodger, FE ;

Mather, JP ;

McNeilly, AS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (04) :1401-1405

[13] Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer [J].

Han, Seung-Su ;

Lee, Sang Hoon ;

Kim, Dong Ho ;

Kim, Jae Weon ;

Park, Noh-Hyun ;

Kang, Soon-Beom ;

Song, Yong Sang .

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2010, 89 (02) :168-174

[14] Squamous cell carcinoma antigen serum levels as prognostic parameter in patients with early stage vulvar cancer [J].

Hefler, LA ;

Sliutz, G ;

Leodolter, S ;

Speiser, P ;

Joura, E ;

Reinthaller, A ;

Kohlberger, P .

GYNECOLOGIC ONCOLOGY, 2005, 97 (03) :904-907

[15] VAB-6 CHEMOTHERAPY CAUSES SPURIOUS ELEVATION OF ALPHA-FETOPROTEIN ASSOCIATED WITH LIVER DYSFUNCTIONS [J].

HIDA, S ;

NISHIMURA, K ;

NISHIO, Y ;

OISHI, K ;

TAKEUCHI, H ;

YOSHIDA, O .

UROLOGIA INTERNATIONALIS, 1991, 46 (01) :1-5

[16] Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? [J].

Hsieh, CH ;

ChangChien, CC ;

Lin, H ;

Huang, EY ;

Huang, CC ;

Lan, KC ;

Chang, SY .

GYNECOLOGIC ONCOLOGY, 2002, 86 (01) :28-33

[17] Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts [J].

Huhtinen, K. ;

Suvitie, P. ;

Hiissa, J. ;

Junnila, J. ;

Huvila, J. ;

Kujari, H. ;

Setala, M. ;

Harkki, P. ;

Jalkanen, J. ;

Fraser, J. ;

Makinen, J. ;

Auranen, A. ;

Poutanen, M. ;

Perheentupa, A. .

BRITISH JOURNAL OF CANCER, 2009, 100 (08) :1315-1319

[18]

HUSSAIN F, 2010, GYNECOLOGIC TUMOR MA

[19]

*IARC WORK GROUP C, 1986, IARC SCI PUBL, V76, P133

[20] Screening for ovarian cancer: a pilot randomised controlled trial [J].

Jacobs, IJ ;

Skates, SJ ;

MacDonald, N ;

Menon, U ;

Rosenthal, AN ;

Davies, AP ;

Woolas, R ;

Jeyarajah, AR ;

Sibley, K ;

Lowe, DG ;

Oram, DH .

LANCET, 1999, 353 (9160) :1207-1210

← 1 2 3 4 5 6 7 →